NEW YORK (GenomeWeb) – Novigenix has signed a commercialization agreement with Dr Risch Medical Laboratory to distribute its PCR-based Colox blood test for early detection of colorectal cancer, giving the firm access to the Swiss German market and Lichtenstein.

The agreement comes after a similar one with Unilabs to target the French Swiss market and is part of the firm's overall European expansion plans.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.